Hypoglycemic and hypolipidemic effect and antioxidant activity of chronic epigallocatechin-gallate in streptozotocin-diabetic rats

Pathophysiology

Volumn 17, Issue 1, 2010, Pages 55-59

  Roghani, Mehrdad ^a   Baluchnejadmojarad, Tourandokht ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes mellitus; Epigallocatechin gallate; Lipid peroxidation

Indexed keywords

EPIGALLOCATECHIN GALLATE; GLIBENCLAMIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 73649149403     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2009.07.004     Document Type: Article

References (30)

1. Vinik A.I., and Vinik E. Prevention of the complications of diabetes. Am. J. Manag. Care 9 (2003) S63-80
2. Reasner C.A. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J. Cardiovasc. Pharmacol. 52 (2008) 136-144
3. Nawale R.B., Mourya V.K., and Bhise S.B. Non-enzymatic glycation of proteins: a cause for complications in diabetes. Indian J. Biochem. Biophys. 43 (2006) 337-344
4. Nishikawa T., and Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid. Redox Signal. 9 (2007) 343-353
5. Wolffe S.P., Jiang Z.Y., and Hunt J.V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic. Biol. Med. 10 (1991) 339-352
6. Lyons T.J. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes?. Diabet. Med. 8 (1991) 411-419
7. Valezquez E., Wincour P.H., Kestsven P., Alberti K.G., and Laker M.F. Relation of lipid peroxides to macrovascular disease in type 2 diabetes. Diabet. Med. 8 (1991) 752-758
8. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414 (2001) 821-827
9. Asgary S., Naderi G.A., Sarraf Zadegan N., and Vakili R. The inhibitory effects of pure flavonoids on in vitro protein glycosylation. J. Herb. Pharmacother. 2 (2002) 47-55
10. Pałgan K., and Drewa G. Flavonoids in medicine. Postepy. Hig. Med. Dosw. 48 (1994) 589-601
11. Laight D.W., Carrier M.J., and Anggard E.E. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc. Res. 47 (2000) 457-464
12. Ajay M., and Mustafa M.R. Chronic treatment with flavonoids prevents endothelial dysfunction in spontaneously hypertensive rat aorta. J. Cardiovasc. Pharmacol. 46 (2005) 36-40
13. Guo Q., Zhao B., Li M., Shen S., and Xin W. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim. Biophys. Acta 1304 (1996) 210-222
14. Kuriyama S., Shimazu T., Ohmori K., Kikuchi N., Nakaya N., Nishino Y., Tsubono Y., and Tsuji I. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. J. Am. Med. Assoc. 296 (2006) 1255-1265
15. Stangl V., Lorenz M., and Stangl K. The role of tea and tea flavonoids in cardiovascular health. Mol. Nutr. Food Res. 50 (2006) 218-228
16. Kao Y.H., Chang H.H., Lee M.J., and Chen C.L. Tea, obesity, and diabetes. Mol. Nutr. Food Res. 50 (2006) 188-210
17. Waltner-Law M.E., Wang X.L., Law B.K., Hall R.K., Nawano M., and Granner D.K. Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J. Biol. Chem. 277 (2002) 34933-34940
18. Li T., Liu J., Zhang X., and Li G. Antidiabetic activity of lipophilic (-)-epigallocatechin-3-gallate derivative under its role of alpha-glucosidase inhibition. Biomed. Pharmacother. 61 (2007) 91-96
19. Song E.K., Hur H., and Han M.K. Epigallocatechin gallate prevents autoimmune diabetes induced by multiple low doses of streptozotocin in mice. Arch. Pharm. Res. 26 (2003) 559-563
20. Yamabe N., Yokozawa T., Oya T., and Kim M. Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J. Pharmacol. Exp. Ther. 319 (2006) 228-236
21. Anton S., Melville L., and Rena G. Epigallocatechin gallate (EGCG) mimics insulin action on the transcription factor FOXO1a and elicits cellular responses in the presence and absence of insulin. Cell Signal. 19 (2007) 378-383
22. Koyama Y., Abe K., Sano Y., Ishizaki Y., Njelekela M., Shoji Y., Hara Y., and Isemura M. Effects of green tea on gene expression of hepatic gluconeogenic enzymes in vivo. Planta Med. 70 (2004) 1100-1102
23. Collins Q.F., Liu H.Y., Pi J., Liu Z., Quon M.J., and Cao W. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase. J. Biol. Chem. 282 (2007) 30143-30149
24. Krentz A.J. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes. Metab. 5 (2003) S19-27
25. Ramesh E., Elanchezhian R., Sakthivel M., Jayakumar T., Senthil Kumar R.S., Geraldine P., and Thomas P.A. Epigallocatechin gallate improves serum lipid profile and erythrocyte and cardiac tissue antioxidant parameters in Wistar rats fed an atherogenic diet. Fundam. Clin. Pharmacol. 22 (2008) 275-284
26. Brown B.G., Zhao X.Q., Sacco D.E., and Albers J.J. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87 (1993) 1781-1791
27. Raederstorff D.G., Schlachter M.F., Elste V., and Weber P. Effect of EGCG on lipid absorption and plasma lipid levels in rats. J. Nutr. Biochem. 14 (2003) 326-332
28. Chen H., Carison E.C., Pellet L., Moritz J.T., and Epstein P.N. Overexpression of metallothionein in pancreatic beta-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes 50 (2001) 2040-2046
29. Bonnefont-Rousselot D., Bastard J.P., Jaudon M.C., and Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab. 26 (2000) 163-176
30. Sriram N., Kalayarasan S., and Sudhandiran G. Enhancement of antioxidant defense system by epigallocatechin-3-gallate during bleomycin induced experimental pulmonary fibrosis. Biol. Pharm. Bull. 31 (2008) 1306-1311